Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

NCT07383298 is registered in ClinicalTrials.gov with Qian Jiang as lead sponsor.

NCT NCT07383298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07383298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
Lead sponsor
Qian Jiang
Phase
Observational
Overall status
Enrolling by invitation
Start date
December 16, 2025
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia